Giannis Mountzios, Consultant Medical Oncologist of the 2nd Oncology Department and Clinical Trials Unit at Henry Dunant Hospital Center, shared a post on X:
“A strategic position statement in Annals of Oncology on the main actions to boost lung cancer research and innovation:
– Pragmatic trials
– Ensure inclusivity and diversity
– NGS in resectable NSCLC
– Exploit resistance mech
– Focus on novel Tox”
Lung cancer research and treatment: global perspectives and strategic calls to action
Authors: M.-L. Meyer, S. Peters, T.S. Mok, S. Lam, P.-C. Yang, C. Aggarwal, J. Brahmer, R. Dziadziuszko, E. Felip, A. Ferris, P.M. Forde, J. Gray, L. Gros, B. Halmos, R. Herbst, P.A. Jänne, B.E. Johnson, K. Kelly, N.B. Leighl, S. Liu, I. Lowy, T.U. Marron, L. Paz-Ares, N. Rizvi, C.M. Rudin, E. Shum, R. Stahel, N. Trunova, P.A. Bunn, F.R. Hirsch
